SERA PROGNOSTICS TO PRESENT AT TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE
MWN-AI** Summary
Sera Prognostics Inc., a leader in maternal and neonatal health diagnostics, has announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2-4, 2026, in Boston. The company's presentation will take place on March 2 at 1:10 p.m. ET, during which management will engage in a fireside chat to discuss recent advancements and milestones in their ongoing mission to enhance pregnancy care through innovative biomarker testing.
Sera Prognostics is recognized for its flagship product, the PreTRM® Test, which is the only widely validated, blood-based biomarker test available for early risk assessment of spontaneous preterm birth in asymptomatic singleton pregnancies. This test identifies proteins in the blood that are predictive of preterm birth, allowing healthcare professionals to make informed decisions regarding the management of pregnancy during critical weeks 18 to 20. The significance of the PreTRM Test is underscored by the alarming statistics surrounding preterm birth, which is noted as a leading cause of neonatal complications and carries substantial long-term health costs. The March of Dimes recently reported that the U.S. continues to struggle with high rates of preterm birth, maintaining a D+ grade for four consecutive years.
The conference will provide a platform for Sera Prognostics not only to showcase the PreTRM Test but also to hold one-on-one meetings with potential investors. A live webcast of the presentation will be accessible on Sera Prognostics' investor relations page, ensuring broader visibility for stakeholders interested in advancements in maternal health technology.
MWN-AI** Analysis
Sera Prognostics Inc. (Nasdaq: SERA), known for its innovative approach in predicting preterm birth through its PreTRM® Test, is set to present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. This presentation could be a pivotal moment for investors, as Sera aims to highlight its recent advancements in maternal and neonatal health.
The company's focus on precision pregnancy care addresses a critical need, given that preterm birth remains the leading cause of infant morbidity and mortality. With the recent March of Dimes Report Card indicating an alarming D+ grade for preterm birth rates in the U.S., the market potential for the PreTRM Test is robust. This blood-based biomarker test uniquely positions Sera in a niche yet significant market—early detection and personalized risk assessment for preterm births, which, if addressed effectively, can mitigate long-term healthcare costs projected to exceed $25 billion annually.
Investors should watch for key takeaways during the presentation, particularly regarding any updates on market acceptance, reimbursement strategies, and competitive positioning. Given that Sera's revenues currently hinge predominantly on the PreTRM Test, signals of growing adoption and relationships with major healthcare providers will be critical indicators of the company’s financial trajectory.
Moreover, the company's strategic conversations, facilitated through one-on-one investor meetings during the conference, provide an opportunity for management to reassure stakeholders about its long-term growth strategy and response to market challenges, including potential regulatory changes and reimbursement landscapes.
In conclusion, while the potential for Sera Prognostics appears promising, prospective investors should maintain vigilance regarding market dynamics, competitive pressures, and the company's ability to execute its growth strategies effectively. Keeping abreast of developments from this conference could yield valuable insights into SERA's future performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SALT LAKE CITY, Feb. 17, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 1:10 p.m. ET. Members of management will participate in a fireside chat, highlighting Sera's latest achievements. The conference, to be held March 2-4, 2026, in Boston, will also include one-on-one investor meetings hosted by the company.
A live webcast of the company's presentation as well as a webcast replay will be available online from the Investors page of the company's website at www.sera.com.
About Sera Prognostics, Inc.
Sera Prognostics is a health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. The company's PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test for early, individualized risk prediction of spontaneous preterm birth. Sera Prognostics is headquartered in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2025 March of Dimes Report Card shows that, for the fourth consecutive year, the United States earned a D+ grade for preterm birth, making the longest stretch of the lowest grade in Report Card history. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.
About the PreTRM® Test
The PreTRM Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company's participation in the above-mentioned conference(s), as well as the date, time, content and webcast replay availability of the Company's presentation(s); and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Contact
Investor Contact
Jennifer Zibuda, Head of Investor Relations
jzibuda@sera.com
+1 (801) 396-8043
SOURCE Sera Prognostics, Inc.
FAQ**
What key milestones and achievements will Sera Prognostics Inc. SERA highlight during the fireside chat at the TD Cowen 46th Annual Health Care Conference?
2. How does Sera Prognostics Inc. SERA plan to address potential competition in the pregnancy biomarker testing market during and after the conference?
3. Can you provide insights on the reception of the PreTRM® Test by healthcare providers and patients, and how Sera Prognostics Inc. SERA is working to enhance its market acceptance?
4. What are Sera Prognostics Inc. SERA's strategies to secure third-party payer coverage for the PreTRM® Test, and how will these strategies be presented at the TD Cowen conference?
**MWN-AI FAQ is based on asking OpenAI questions about Sera Prognostics Inc. (NASDAQ: SERA).
NASDAQ: SERA
SERA Trading
-6.52% G/L:
$1.935 Last:
14,756 Volume:
$1.96 Open:
